Oscient reiterated at strong buy by JMP

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at a strong buy following the company's reported second-quarter Factive sales of $2.6 million, lower than JMP's $5.5 million estimate. Total revenue of $4.6 million also fell short of the analyst's estimate of $7.5 million and the Street estimate of $7.9 million. According to the analyst, the purchase of cardiovascular drug Antara, expected to close in August, could be a major catalyst for Oscient, if successful. Shares of the Waltham, Mass.-based biopharmaceutical company were down 6 cents, or 6.56%, at $1.14, on volume of 1,185,782 shares versus the three-month running average of 571,844 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.